Dear EURETINA Members, A very warm welcome to the September 9th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »September 9th, 2024 “EURETINA-Brief” Issue No. 299
Researchers at Moorfields Eye Hospital, the UCL Institute of Ophthalmology, University College London and the Shiley Eye Institute, University of California, San Diego, has reported… Read More »Variants on the TMEM216 gene suggests an under-reporting from certain ancestry cohorts on non-syndromic retinitis pigmentosa (RP).
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the Department of Ophthalmology, University of Oslo, Norway, have published a… Read More »A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck. EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland
Researchers based at the MRC Human Genetics Unit, at the University of Edinburgh, and the Western General Hospital (Edinburgh), have reported a new study indicating… Read More »X-linked retinitis pigmentosa (XLRP) due to RPGR variants report new data on actin dynamics.
The expansion on the field of genetics and genomics is reflective to the changes of the average 6.4 years between each of the nine editions… Read More »Book Review of Thompson & Thompson’s Genetics and Genomics in Medicine, 9th edition (Elsevier).
